For research use only. Not for therapeutic Use.
AZD-5672 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC50=7.3 μM). AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC50=32 μM). AZD-5672 can be used for the research of rheumatoid arthritis[1][2][3].
AZD-5672 (0, 0.1, 0.3, 1, 3, 10, 30, and 100 μM) inhibits P-gp-mediated digoxin transport in a concentration-dependent manner (mean apparent IC50: 32 μM) in Caco-2 cells[2].
In vivo pharmaeokineties data for AZD-5672 (compound 1)[1]
Species
CIa(mL/min/kg)
Vssa (L/kg)
t1/2a (h)
Fb (%)
Rat
28
5.3
2.6
38
Dog
18
5.7
3.9
86
a AZD-5672 dosed 1-2 mg/kg i.v.
b AZD-5672 dosed 2-5 mg/kg p.o.
| Catalog Number | I003735 |
| CAS Number | 780750-65-4 |
| Synonyms | N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide |
| Molecular Formula | C32H38F2N2O5S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C32H38F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-12,20-22,28,31H,4,13-19H2,1-3H3/t31-/m1/s1 |
| InChIKey | SCXSQUUTGCWHFU-WJOKGBTCSA-N |
| SMILES | CCN(C1CCN(CC1)CCC(C2=CC=C(C=C2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C |
| Reference | [1]. Cumming JG, et al. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1655-9. [2]. Elsby R, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011 Feb;39(2):275-82. [3]. Gerlag DM, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010 Nov;62(11):3154-60. |
